how many people are using glp-1 Poll: 1 in 8 Adults Say They've Taken a Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease Just how many Americans are

Taylor Strecker takes the WW x Mother Issue screen test

doi: 10.1016/s0026-0495(99)90232-9

Hypothalamic CaMKK2 contributes to the regulation of energy balance

Eat more probiotic foods such as yogurt, kefir, kimchi, or sauerkraut, or take supplements

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects

Why Glucagon Receptor Agonism Adds Value The addition of glucagon receptor activation to the GIP/GLP-1 backbone introduces several theoretical advantages: Increased energy expenditure: Glucagon receptor activation promotes hepatic glycogenolysis and gluconeogenesis and may increase resting metabolic rate, addressing one of the key limitations of incretin-based therapy where metabolic adaptation can slow weight loss over time Hepatic fat reduction: Glucagon signaling promotes hepatic lipid oxidation, which may provide superior benefits for patients with metabolic dysfunction-associated steatohepatitis (MASH) Preserved lean mass: Early data suggest that the increased energy expenditure from glucagon agonism may help preserve lean body mass during weight loss, though this requires confirmation in larger trials Clinical Implications for Current Practice While retatrutide is not yet FDA-approved, providers should be aware of its development as it will likely reshape the obesity pharmacotherapy landscape upon approval